Find IAIM on FacebookFind IAIM on LinkedIn

Sûreté des injections

Appalachia Gripped by Hepatitis C Epidemic, Bracing for HIV

Patton Couch shook his head and clenched his teeth, recounting the night four years ago when he plucked a dirty needle from a pile at a flophouse and jabbed it into his scarred arm.
 
He knew the odds; most of the addicts in the room probably had hepatitis C.
 
"All I cared about was how soon and how fast I could get it in," he says. "I hated myself, it was misery. But when you're in the grips of it, the only way I thought I could escape it was one more time."
 
Undefined

Vaccines - a needle-free future? An interview with Thomas Johnston and Dr. Kees Leenhouts, Mucosis

Vaccination was started by a gentleman named Edward Jenner who, while dealing with young boys that milked cows, came to the conclusion that there must be a way of using cowpox to vaccinate children against smallpox. For some time, he researched cowpox, which is a milder disease than small pox. Eventually, he was able to show that by exposing children to the virus, they could become protected from smallpox.
 
Undefined

NIH-backed West Nile candidate enters PhI trials at Duke

Despite years of efforts from academia and the industry, including Merck, no FDA-approved West Nile virus vaccine exists. Scientists from Oregon Health & Science University (OHSU) are looking to change that.

Undefined

NewLink continues cancer vaccine Ph III trial with interim data under wraps

Without sharing interim data to prove a win for NewLink Genetics' late-stage pancreatic cancer vaccine, it will go full steam ahead on its Phase III trial, the company announced Monday.

Undefined

Ebola news: GSK, Emergent start Phase I trial; Bavarian Nordic scores €50M for vaccine development

In a big week for Ebola vaccines, Emergent Biosciences and GlaxoSmithKline have begun a Phase I trial of their candidates, while Bavarian Nordic received €50 million ($56 million) in loans from the European Investment Bank that go in

Undefined

Bavarian Nordic smallpox vaccine scores two late-stage trial wins

Though it's been eradicated, the threat of a smallpox outbreak is taken very seriously by public health officials, an ongoing concern that's helped Bavarian Nordic pay its bills through the years.

With an announcement Wednesday trumpeting two successful late-stage tests, the company has reason to believe it can advance its business with smallpox vaccine Imvamune.

Undefined

Mexico suspends infant vaccines after two babies die and 29 fall ill

Mexico’s public health system has suspended infant vaccines and begun an investigation after two babies died and 29 became ill in an impoverished community in southern Mexico.
 
The Mexican institute for social security says six of the 29 babies are in grave condition after receiving vaccinations for tuberculosis, rotavirus and hepatitis B.
 
The cause of the adverse reactions is not known, the institute said Sunday.
 
Undefined

Autisme : aucun lien avec le vaccin contre la rougeole

Des enquêtes menées auprès de parents ayant un enfant souffrant d'autisme suggèrent qu'un grand nombre d’entre eux pensent que le vaccin contre la rougeole a contribué à l’apparition de ce trouble. Pourtant, cette méfiance grandissante envers les vaccins serait injustifiée. Une nouvelle étude scientifique américaine vient en effet de conclure qu’il n’existerait aucun lien entre le vaccin contre la rougeole, les oreillons et la rubéole (ROR) et les troubles de l’autisme.
 
Undefined

Potency worries prompt GSK flu vaccine recall

To cap off one of the least effective seasons for flu vaccines in recent memory, vaccine producer GlaxoSmithKline ($GSK) announced the recall of all remaining doses of a quadrivalent, affecting roughly 1.7 million jabs.
 
Undefined

GSK recalls vaccine made at troubled plant in Canada

GlaxoSmithKline ($GSK) is recalling 1.7 million doses of its quadrivalent flu vaccine that was manufactured at a plant that ran into a series of manufacturing issues last year including an FDA warning letter. The company says there are questions about whether the vaccine is retaining its potency.
 
Undefined

Pages

© 2017 • SABIN VACCINE INSTITUTE
• 2175 K STREET, NW, SUITE 400 • WASHINGTON, DC 20037, USA • +1 202 842 5025
 
Find IAIM on FacebookFind IAIM on LinkedIn
Find IAIM on FacebookFind IAIM on LinkedIn